Export this Data | Chart Risk Level by Product Clear Chart
Add More Filters: Active_ingredient, Contact_time, Formulation_type, Why_on_List_N,
Risk_level ✖
Surface_type (array) ✖
ID | EPA_reg_num | Risk_level | Active_ingredient | Product_name | Company ▼ | Use_site | Surface_type | Contact_time | Formulation_type | Follow_directions_for_this_virus | Date_on_List_N | Why_on_List_N |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1078 | 6836-357 | Increased Risk | Quaternary ammonium | Carbosan 20D | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) | 5.0 minutes | Dilutable | Norovirus | 2020-08-20 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1079 | 6836-358 | Increased Risk | Quaternary ammonium | Carbosan 7.5D | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) | 5.0 minutes | Dilutable | Norovirus | 2020-08-20 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1080 | 6836-356 | Increased Risk | Quaternary ammonium | Carbosan 50D | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) | 5.0 minutes | Dilutable | Norovirus | 2020-08-20 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1095 | 6836-336 | Increased Risk | Quaternary ammonium | Lonza Disinfectant Wipes Plus | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 4.0 minutes | Wipe | SARS-CoV-2 | 2020-08-06 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1096 | 6836-382 | Increased Risk | Quaternary ammonium | Nugen Low Streak Disinfectant Wipes | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 4.0 minutes | Wipe | SARS-CoV-2 | 2020-08-06 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1097 | 6836-313 | Increased Risk | Quaternary ammonium | Lonza Disinfectant Wipes | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 4.0 minutes | Wipe | SARS-CoV-2 | 2020-08-06 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1099 | 6836-136 | Increased Risk | Quaternary ammonium | Lonza Formulation S-18F | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-13 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1100 | 6836-140 | Increased Risk | Quaternary ammonium | Lonza Formulation S-21F | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-13 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1101 | 6836-152 | Increased Risk | Quaternary ammonium | Lonza Formulation DC-103 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Ready-to-use | SARS-CoV-2 | 2021-04-13 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1102 | 6836-77 | Increased Risk | Quaternary ammonium | Lonza Formulation S-18 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-13 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1103 | 6836-381 | Increased Risk | Quaternary ammonium | Lonzagard R-82G | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-13 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1104 | 6836-139 | Increased Risk | Quaternary ammonium | Lonza Formulation R-82F | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-13 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1105 | 6836-346 | Increased Risk | Quaternary ammonium | Lonzagard RCS-256 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-27 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1106 | 6836-347 | Increased Risk | Quaternary ammonium | Lonzagard RCS-128 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-27 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1107 | 6836-348 | Increased Risk | Quaternary ammonium | Lonzagard RCS-128 PLUS | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-27 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1108 | 6836-349 | Increased Risk | Quaternary ammonium | Lonzagard RCS-256 Plus | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-27 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1109 | 6836-75 | Increased Risk | Quaternary ammonium | Lonza Formulation S-21 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-13 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1110 | 6836-78 | Increased Risk | Quaternary ammonium | Lonza Formulation R-82 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-13 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1214 | 6836-333 | Increased Risk | Quaternary ammonium | MMR-4U | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) | 10.0 minutes | Ready-to-use | Feline calicivirus; Norovirus | 2020-03-26 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19) |
1296 | 6836-245 | Increased Risk | Quaternary ammonium | CSP-46 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) | 2.0 minutes | Ready-to-use | SARS-CoV-2 | 2021-07-13 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1297 | 6836-379 | Increased Risk | Quaternary ammonium | Nugen NR Disinfecant Wipes | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN); Food Contact No Rinse (FCNR) | 5.0 minutes | Wipe | Norovirus | 2020-05-07 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1298 | 6836-372 | Increased Risk | Quaternary ammonium | Nugen 2m Disinfectant Wipes | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Wipe | SARS-CoV-2 | 2020-05-07 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1331 | 6836-385 | Safer | Hydrogen peroxide | DS-6640 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Ready-to-use | SARS-CoV-2 | 2021-03-30 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1332 | 6836-388 | Safer | Hydrogen peroxide | DS6809 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Wipe | SARS-CoV-2 | 2021-03-30 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1359 | 6836-233 | Increased Risk | Quaternary ammonium | BARDAC 205M-50 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 10.0 minutes | Dilutable; Electrostatic spray | Norovirus | 2020-04-16 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1438 | 6836-277 | Increased Risk | Quaternary ammonium | BARDAC 205M-1.30 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 10.0 minutes | Dilutable; Electrostatic Spray | Norovirus | 2020-03-13 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1439 | 6836-303 | Increased Risk | Quaternary ammonium | BARDAC 205M-5.2 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 10.0 minutes | Dilutable; Electrostatic Spray | Norovirus | 2020-03-13 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1440 | 6836-362 | Increased Risk | Quaternary ammonium | Nugen MB5A-128 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-03-02 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1441 | 6836-363 | Increased Risk | Quaternary ammonium | Nugen MB5A-64 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-03-02 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1442 | 6836-366 | Increased Risk | Quaternary ammonium | Nugen MB5N-64 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-27 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1478 | 6836-266 | Increased Risk | Quaternary ammonium | BARDAC 205M-10 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) | 10.0 minutes | Dilutable; Electrostatic Spray | Norovirus | 2020-03-03 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1479 | 6836-278 | Increased Risk | Quaternary ammonium | BARDAC 205M- 14.08 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 10.0 minutes | Dilutable; Electrostatic Spray | Norovirus | 2020-03-03 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1480 | 6836-289 | Increased Risk | Quaternary ammonium | BARDAC 205M RTU | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) | 10.0 minutes | Ready-to-use; Electrostatic Spray | Norovirus | 2020-03-03 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1481 | 6836-302 | Increased Risk | Quaternary ammonium | BARDAC 205M-2.6 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) | 10.0 minutes | Dilutable; Electrostatic Spray | Norovirus | 2020-03-03 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1482 | 6836-305 | Increased Risk | Quaternary ammonium | BARDAC 205M-23 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) | 10.0 minutes | Dilutable; Electrostatic Spray | SARS-CoV-2 | 2020-03-03 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1483 | 6836-361 | Increased Risk | Quaternary ammonium | Nugen MB5A-256 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-03-02 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1484 | 6836-364 | Increased Risk | Quaternary ammonium | Nugen MB5N-256 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-27 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1485 | 6836-365 | Increased Risk | Quaternary ammonium | Nugen MB5N-128 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 1.0 minutes | Dilutable | SARS-CoV-2 | 2021-04-27 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1486 | 6836-70 | Increased Risk | Quaternary ammonium | BARDAC 205M-7.5 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 10.0 minutes | Dilutable; Electrostatic Spray | Norovirus | 2020-03-03 | Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1701 | 6836-445 | Increased Risk | PHMB; Quaternary ammonium | Nugen NR RTU | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 4.0 minutes | Ready-to-use | SARS-CoV-2 | 2021-02-11 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1702 | 6836-446 | Increased Risk | PHMB; Quaternary ammonium | Nugen NR-128 | Arxada, LLC | Healthcare; Institutional; Residential | Hard Nonporous (HN) | 4.0 minutes | Dilutable | SARS-CoV-2 | 2021-02-11 | Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
Safer Disinfectants is a project of the Maryland Pesticide Education Network
© 2021. All rights reserved.